Jun 2026 (Q2 FY26) — Jul 30, 2026
ICON Q2 FY26 — Strong Bookings and AI Collaboration
Read the full callICON (ICLR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ICON earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2,063 | +1.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 6.7 | −4.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 72.6 | −64.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$168.14 −1.20% · −$2.04
Performance −9.1% 1Y
1Y: $185.06 on 17 Oct 2025 → $168.14. High $202.92 (7 Jan 2026), low $80.08 (12 Feb 2026).
- Previous close
- $170.18
- 52-week range
- $80.08 – $202.92
- One year
- −10.78%
Overview
- Symbol
- ICLR
- Sector
- Industrials
- Industry
- Services-Commercial Physical & Biological Research
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Jun 24, 2026
ICON plc Q1 FY26 — Strong Bookings & Reaffirmed Guidance
Read the full callEvery analysed call
ICON earnings calls (ICLR)
Financials
What the filings say
Net profit, year on year: −64% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,042 | 2,041 | 2,015 | 2,039 | 2,084 | 2,113 | 2,034 | 2,063 |
| Expenses | 1,739 | 1,744 | 1,788 | 1,808 | 2,307 | 1,905 | 1,860 | 1,926 |
| Operating profit | 303 | 297 | 227 | 231 | -223 | 208 | 174 | 138 |
| Operating margin | 14.8% | 14.6% | 11.3% | 11.3% | −10.7% | 9.8% | 8.5% | 6.7% |
| Interest | 53 | 51 | 48 | 50 | 50 | 49 | 48 | 49 |
| Profit before tax | 252 | 347 | 181 | 183 | -271 | 160 | — | 92 |
| Tax rate | 15.3% | −3.3% | 11.2% | −11.3% | −4.7% | 6.7% | — | 21.3% |
| Net profit | 213 | 347 | 161 | 204 | -284 | 149 | 105 | 73 |
| EPS ($ per share) | 2.57 | — | 2 | 2.57 | -3.67 | — | 1.37 | 0.94 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 7 | 7 | 7 | 7 | 6 |
| Reserves | 888 | 1,110 | 1,263 | 1,416 | 1,821 | 2,404 | 2,643 | 2,122 |
| Total liabilities | 1,000 | 1,250 | 1,585 | 9,320 | 8,687 | 7,653 | 7,193 | 7,076 |
| Fixed assets | 159 | 165 | 174 | 336 | 350 | 361 | 383 | 396 |
| Total assets | 2,354 | 2,908 | 3,436 | 17,387 | 17,185 | 16,865 | 16,635 | 16,270 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 269 | 413 | 568 | 829 | 563 | 1,161 | 1,287 | 1,036 |
| Cash from investing | -37 | -162 | -47 | -6,024 | -146 | -227 | -267 | -188 |
| Cash from financing | -113 | -125 | -208 | 5,115 | -864 | -844 | -837 | -771 |
| Net cash flow | 113 | 124 | 320 | -88 | -463 | 89 | 161 | 109 |
| Capital expenditure | -48 | -39 | -41 | -94 | -142 | -141 | -168 | -174 |
| Free cash flow | 220 | 374 | 527 | 735 | 421 | 1,020 | 1,119 | 862 |
ICLR operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Gross bookings | $3.3BQuarter 1 gross bookings were $3.3 billion, matching the strong performance in quarter 4 2025 and up 22% year-over-year.Source: earnings call transcript | $3.7BQ2 gross business wins were $3.7 billion, an increase of 24% year-over-year and 13% sequentially with strong performance across the portfolio.Source: earnings call transcript | +12.1% |
| Cancellations | $383MCancellations were also in line with the improved level seen in quarter 4, a total of $383 million for the quarter.Source: earnings call transcript | $562MCancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x.Source: earnings call transcript | +46.7% |
| Net business wins | $2.88BStrength of gross bookings and cancels resulted in net business wins of $2.88 billion in the quarter, an increase of 42% year-over-year and a net book-to-bill of 1.42x.Source: earnings call transcript | $3.1BCancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x.Source: earnings call transcript | +7.6% |
| Net book-to-bill | 1.42 xStrength of gross bookings and cancels resulted in net business wins of $2.88 billion in the quarter, an increase of 42% year-over-year and a net book-to-bill of 1.42x.Source: earnings call transcript | 1.51 xCancellations totaled $562 million, broadly in line with expectations, resulting in net bookings of $3.1 billion and a net book-to-bill ratio of 1.51x.Source: earnings call transcript | +6.3% |
| Book-to-bill Direct fee | 1.3 x+Encouragingly, we again saw a solid contribution of direct fee versus pass-through awards with our book-to-bill on a direct fee basis in excess of 1.3x for the quarter.Source: earnings call transcript | 1.2 xDirect fee bookings also remained strong, resulting in a direct fee net book-to-bill ratio of 1.2x.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
50 filings between Aug 7, 2026 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.04M
37 sales by 9 insiders
Compensation
not trading decisions- 13
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| CLIMAX JOHN DR | — | $1.01M | Sep 16, 2026 |
| Murphy Ronan Martin | — | $1.01M | Sep 17, 2026 |
| McCague Eugene Pacelli | — | $707.8K | Sep 17, 2026 |
| Murray Ciaran | — | $439.8K | Aug 11, 2026 |
| Clerkin Nigel Bernard John | — | $372.4K | Aug 11, 2026 |
| O'Neill Julie | — | $150.3K | Aug 11, 2026 |
| Grais Linda | — | $138.2K | Aug 11, 2026 |
| Whitaker Anne Clem | — | $138.2K | Aug 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | McCague Eugene Pacelli Director | Sale | 3,255 | $569.6K |
| Sep 17, 2026 | McCague Eugene Pacelli Director | Option exercise | 3,255 | $409.3K |
| Sep 17, 2026 | Murphy Ronan Martin Director | Option exercise | 5,005 | $629.3K |
| Sep 17, 2026 | Murphy Ronan Martin Director | Sale | 5,005 | $875.9K |
| Sep 16, 2026 | CLIMAX JOHN DR Director | Sale | 5,005 | $875.9K |
| Sep 16, 2026 | CLIMAX JOHN DR Director | Option exercise | 5,005 | $629.3K |
| Aug 11, 2026 | CLIMAX JOHN DR Director | Sale | 95 | $15.6K |
| Aug 11, 2026 | CLIMAX JOHN DR Director | Sale | 591 | $97.2K |
| Aug 11, 2026 | CLIMAX JOHN DR Director | Sale | 67 | $11.1K |
| Aug 11, 2026 | Grais Linda Director | Sale | 87 | $14.2K |
| Aug 11, 2026 | Grais Linda Director | Sale | 97 | $15.9K |
| Aug 11, 2026 | Grais Linda Director | Sale | 590 | $97.0K |
| Aug 11, 2026 | Grais Linda Director | Sale | 67 | $11.1K |
| Aug 11, 2026 | McCague Eugene Pacelli Director | Sale | 88 | $14.3K |
| Aug 11, 2026 | McCague Eugene Pacelli Director | Sale | 96 | $15.7K |
| Aug 11, 2026 | McCague Eugene Pacelli Director | Sale | 590 | $97.0K |
| Aug 11, 2026 | McCague Eugene Pacelli Director | Sale | 67 | $11.1K |
| Aug 11, 2026 | Murphy Ronan Martin Director | Sale | 88 | $14.3K |
| Aug 11, 2026 | Murphy Ronan Martin Director | Sale | 96 | $15.7K |
| Aug 11, 2026 | Murphy Ronan Martin Director | Sale | 590 | $97.0K |
| Aug 11, 2026 | Murphy Ronan Martin Director | Sale | 67 | $11.1K |
| Aug 11, 2026 | Whitaker Anne Clem Director | Sale | 88 | $14.3K |
| Aug 11, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Sale | 237 | $38.6K |
| Aug 11, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Sale | 259 | $42.4K |
| Aug 11, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Sale | 1,591 | $261.7K |
| Aug 11, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Sale | 180 | $29.8K |
| Aug 11, 2026 | CLIMAX JOHN DR Director | Sale | 88 | $14.3K |
| Aug 11, 2026 | Murray Ciaran Director | Sale | 280 | $45.6K |
| Aug 11, 2026 | Murray Ciaran Director | Sale | 305 | $49.9K |
| Aug 11, 2026 | Murray Ciaran Director | Sale | 1,880 | $309.2K |
| Aug 11, 2026 | Murray Ciaran Director | Sale | 212 | $35.1K |
| Aug 11, 2026 | O'Neill Julie Director | Sale | 95 | $15.5K |
| Aug 11, 2026 | O'Neill Julie Director | Sale | 105 | $17.2K |
| Aug 11, 2026 | O'Neill Julie Director | Sale | 642 | $105.6K |
| Aug 11, 2026 | O'Neill Julie Director | Sale | 73 | $12.1K |
| Aug 11, 2026 | Whitaker Anne Clem Director | Sale | 96 | $15.7K |
| Aug 11, 2026 | Whitaker Anne Clem Director | Sale | 590 | $97.0K |
| Aug 11, 2026 | Whitaker Anne Clem Director | Sale | 67 | $11.1K |
| Aug 10, 2026 | CLIMAX JOHN DR Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | Murray Ciaran Director | Option exercise | 2,677 | — |
| Aug 10, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Option exercise | 3,375 | — |
| Aug 10, 2026 | Clerkin Nigel Bernard John Chief Financial Officer | Option exercise | 918 | — |
| Aug 10, 2026 | Grais Linda Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | Whitaker Anne Clem Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | Murphy Ronan Martin Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | McCague Eugene Pacelli Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | O'Neill Julie Director | Option exercise | 1,732 | — |
| Aug 10, 2026 | Balfe Barry Edward Chief Executive Officer | Sale | 304 | $49.8K |
| Aug 10, 2026 | Balfe Barry Edward Chief Executive Officer | Sale | 78 | $12.9K |
| Aug 7, 2026 | Balfe Barry Edward Chief Executive Officer | Option exercise | 728 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ICON PLC
Free account. Everything above stays public.
Write why you follow ICON PLC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading